Skip to main content

Liraglutide News (Page 4)

Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes

PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ – Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for...

FDA Medwatch Alert: Incretin Mimetic Drugs for Type 2 Diabetes: Early Communication - Reports of Possible Increased Risk of Pancreatitis and Pre-cancerous Findings of the Pancreas

ISSUE: FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis and pre-cancerous cellular changes called pancreatic duct...

Victoza Label Updated to Include Data Showing Superior Efficacy When Compared to Januvia

Princeton, N.J. (April 9, 2012) /PRNewswire/ - Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza (liraglutide [rDNA origin]...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Weight Loss (Obesity / Overweight), Diabetes, Type 2, Cardiovascular Risk Reduction

Related drug support groups

Saxenda, Victoza

Liraglutide patient information at Drugs.com